These transactions were part of a routine process involving automatic sales to cover tax liabilities related to restricted stock units. Following these transactions, Devers will own 15,937 shares of Ionis common stock. Additionally, Devers was granted 33,000 restricted stock units and 22,000 performance restricted stock units, which may vest in the future based on specified performance criteria. according to InvestingPro According to the data, analysts maintain a bullish outlook on the stock with a consensus recommendation of 1.84 (Strong Buy), and the company maintains an overall financial health score of “Fair.” For deeper insights into insider trading patterns and comprehensive analysis, InvestingPro offers detailed research reports covering more than 1,400 US stocks, including IONS. according to InvestingPro According to the data, analysts maintain a bullish outlook on the stock with a consensus recommendation of 1.84 (Strong Buy), and the company maintains an overall financial health score of “Fair.” For deeper insights into insider trading patterns and comprehensive analysis, InvestingPro offers detailed research reports covering more than 1,400 US stocks, including IONS.
These transactions were part of a routine process involving automatic sales to cover tax liabilities related to restricted stock units. Following these transactions, Devers will own 15,937 shares of Ionis common stock. Additionally, Devers was granted 33,000 restricted stock units and 22,000 performance restricted stock units, which may vest in the future based on specified performance criteria.
In other recent news, Ionis Pharmaceuticals (NASDAQ:) maintained its positive standing with Piper Sandler and Needham, following FDA approval of olizarsen (TRYNGOLZA) for adults with familial chylomicronemia syndrome (FCS). This approval marks the first single commercial drug launch for Ionis Pharmaceuticals, with the drug priced at $595,000 per year, in line with expectations for therapies targeting ultra-rare diseases. The company plans to transition patients from Open-Label Extension (OLE) and Expanded Access Program (EAP) to commercial drug during the first half of 2025. Piper Sandler expects $37 million in US FCS revenue for fiscal 2025, while Needham maintains $37 million of US FCS revenues for fiscal year 2025. Buy rating for Ionis.
Additionally, Ionis Pharmaceuticals recently announced its third-quarter 2024 financial results, with a focus on non-GAAP financials, indicating confidence in its operating management and long-term prospects. The company's revenue forecast for TRYNGOLZA in 2025 is US$27 million, slightly below the current consensus estimate of US$28 million. However, this may change with the expected future approval of an indication for severe hypertriglyceridemia.
Finally, Ionis expects positive results from pivotal studies of severe hypertriglyceridemia (sHTG) in the second half of 2025. Analysts from Needham and TD Cowen expressed confidence in the company's market position and TRYNGOLZA's potential. These latest developments underscore Ionis Pharmaceuticals' progress and potential in the pharmaceutical industry.
This article was created with the power of artificial intelligence and reviewed by an editor. For more information, see our terms and conditions.
